Solution: To develop a serological test for detection of presence and quantity of antibodies to SARS-COV-2 infection. The team would repurpose a testing method that has already been applied successfully in sample analyses for food and pharmaceutical industry. The necessary adjustments are minor, principally comprising only use of different antibodies. The iqPCR‐FAST-SerCoV® response kit would detect the IgG and IgM types of antibodies corresponding to SARSCOV‐2 response in human serum samples. While IgM is one of the first types of antibodies produced after infection and is most useful for determining recent infection, the IgG generally develops later and may remain detectable for months or years. The test can detect the quantity as small as only one molecule of antibody present in the sample (team’s data shows up to 1000 times better detection than ELISA methods) and can determine if the quantity of antibodies is rising over time, thus allowing assessment of immunity development. The test is very fast and gives results for up to 90 analysed samples, within 3 hours of obtaining the prepared samples. The test results and analysis would be available in Open Data format. The primary kit will be developed and validated on a lab scale, including inter-laboratory validation.